{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:30:41Z","timestamp":1768869041913,"version":"3.49.0"},"reference-count":10,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,3,25]],"date-time":"2018-03-25T00:00:00Z","timestamp":1521936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Edoxaban was extracted from human plasma by simple protein precipitation with acetonitrile, followed by quantitative determination using a liquid chromatography\u2013mass spectrometry method. The recoveries of edoxaban and the internal standard (ticlopidine) from human plasma were &gt;85%, and the within\u2010 and between\u2010day coefficients of variation were within 15%. The limit of quantification in human plasma was 1\u2009ng\/mL. The concentration of edoxaban in blood decreased at room temperature, but remained unchanged for 1\u2009week at 4\u00b0C. On the other hand, the concentration in plasma at both \u221220 and \u221280\u00b0C remained unchanged for 5\u2009months. These results indicated that blood samples should be centrifuged immediately or stored at 4\u00b0C, and that plasma samples should be stored below \u221220\u00b0C until analysis. This method was applied to human plasma obtained from four patients after total knee arthroplasty. Analysis of edoxaban pharmacokinetics demonstrated an absorption time lag of 4h, a maximum concentration of 110 \u00b1 26\u2009ng\/mL and an oral clearance of 37 \u00b1 16\u2009L\/h. The analytical methods established in this study will be suitable for determining the concentrations of edoxaban in human plasma.<\/jats:p>","DOI":"10.1002\/bmc.4213","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T08:52:47Z","timestamp":1518771167000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A quantitative LC\/MSMS method for determination of edoxaban, a Xa inhibitor and its pharmacokinetic application in patients after total knee arthroplasty"],"prefix":"10.1002","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9041-5589","authenticated-orcid":false,"given":"Kazuhiko","family":"Hanada","sequence":"first","affiliation":[{"name":"Department of Biopharmaceutics Meiji Pharmaceutical University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin\u2010ichi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics Meiji Pharmaceutical University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichi","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Kitasato Institute Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Kitasato Institute Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Tsukimura","sequence":"additional","affiliation":[{"name":"Center for Joint Prosthesis and Cartilage Grafting Kitasato Institute Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harumi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics Meiji Pharmaceutical University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100399"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.3170"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000059"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2013.07.009"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1120718"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1055\/s-0038-1651032","article-title":"The relationship between anti\u2010factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement","volume":"62","author":"Levine M. N.","year":"1989","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010370974"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.9.2337.2337"},{"key":"e_1_2_8_10_1","unstructured":"US Food and Drug Administration.2013.Guidance for Industry: Bioanalytical Method Validation.https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm368107.pdf (Accessed 1 March 2018)."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-016-1367-y"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbmc.4213","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.4213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:31:39Z","timestamp":1760041899000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.4213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,25]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1002\/bmc.4213"],"URL":"https:\/\/doi.org\/10.1002\/bmc.4213","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,25]]},"assertion":[{"value":"2017-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e4213"}}